Children's Mercy Hospital

Running trials

• Recruiting

  Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)

  NCT07582861· Carelon Research· Source

• Recruiting

  BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart Disease

  NCT07582848· Carelon Research· Source

• Recruiting

  Phentermine's Impact on Treatment in Teens

  NCT07282340· Phase 2· Russell McCulloh, MD· Source

• Recruiting

  Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

  NCT06834594· Phase 4· Children's Mercy Hospital Kansas City· Source

• Recruiting

  A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  NCT06941272· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

  NCT06783309· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

  NCT06654752· University of Washington, the Collaborative Health Studies Coordinating Center· Source

• Recruiting

  Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

  NCT06554288· Phase 1· Children's Mercy Hospital Kansas City· Source

• Recruiting

  A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

  NCT05849662· Phase 1/2· Therapeutic Advances in Childhood Leukemia Consortium· Source

• Active, not recruiting

  Bionic Pancreas in CFRD

  NCT06449677· Phase 3· Jaeb Center for Health Research· Source

• Recruiting

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Happy Bob App: A Preliminary Evaluation of Its Use in Youth With Diabetes

  NCT06412601· Children's Mercy Hospital Kansas City· Source

• Active, not recruiting

  A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

  NCT06412666· Phase 2/3· Cytokinetics· Source

• Recruiting

  Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  NCT06177067· Phase 1· St. Jude Children's Research Hospital· Source

• Recruiting

  Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

  NCT05958316· Virginia Commonwealth University· Source

• Recruiting

  Cord Clamping Among Neonates With Congenital Heart Disease

  NCT06153459· Carl Backes, MD· Source

• Active, not recruiting

  Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

  NCT03929601· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Active, not recruiting

  Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

  NCT05743244· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Enrolling by invitation

  CHAMP App Cardiac Study and Repository

  NCT06034392· Lori Erickson· Source

• Enrolling by invitation

  Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

  NCT05844449· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

  NCT05594563· Phase 2· Emily K. Sims· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

  NCT05500807· Phase 1· Bleeding and Clotting Disorders Institute Peoria, Illinois· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Active, not recruiting

  A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

  NCT05330325· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

  NCT05422222· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Ferric Citrate and Chronic Kidney Disease in Children

  NCT04741646· Phase 2· University of California, Los Angeles· Source

• Active, not recruiting

  A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

  NCT05135559· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  NCT05082519· Phase 2· Etan Orgel· Source

• Active, not recruiting

  Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

  NCT05112237· Tenaya Therapeutics· Source

• Recruiting

  BSGM to Evaluate Patients With GI Symptoms

  NCT05880199· Children's Hospital of Philadelphia· Source

• Recruiting

  Liver Adiposity Effects on Pediatric Statin

  NCT04903223· Phase 1· Children's Mercy Hospital Kansas City· Source

• Recruiting

  ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

  NCT04398628· American Thrombosis and Hemostasis Network· Source

• Recruiting

  A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

  NCT05999994· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

  NCT03876769· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  NCT03509961· Phase 2· Pediatric Transplantation & Cellular Therapy Consortium· Source

• Recruiting

  A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

  NCT03619850· Phase 3· AMAG Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

  NCT02932150· Phase 2· Gilead Sciences· Source

• Recruiting

  Early PKD Observational Cohort Study

  NCT02936791· University of Kansas Medical Center· Source

• Recruiting

  Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

  NCT02418442· Duke University· Source

• Active, not recruiting

  Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

  NCT02574728· Phase 2· Emory University· Source

• Active, not recruiting

  Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

  NCT01659606· Phase 2· Boston Children's Hospital· Source

• Recruiting

  International (Pediatric) Peritoneal Biobank

  NCT01893710· Heidelberg University· Source

• Recruiting

  TrialNet Pathway to Prevention of T1D

  NCT00097292· University of South Florida· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers8 recruiting
• Chronic kidney disease4 recruiting
• Congenital heart disease4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Cystic fibrosis2 recruiting
• Haemophilia2 recruiting
• Obesity2 recruiting
• Type 1 diabetes2 recruiting
• Acute myeloid leukaemia1 recruiting
• Cerebral palsy1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Dystonia1 recruiting
• Gastroparesis1 recruiting
• High blood pressure1 recruiting
• Neuroblastoma1 recruiting
• Polycystic kidney disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting
• Thalassaemia1 recruiting
• Turner syndrome1 recruiting

Closed trials

• Withdrawn

  A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

  NCT06395090· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Children's Mercy Teens With Type 1 Diabetes Will Participate in an Online Peer Support Group.

  NCT06412146· Children's Mercy Hospital Kansas City· Source

• Terminated

  STOP-T1D Low-Dose (ATG)

  NCT04291703· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  WIReD: Wireless Interstage Remote Device Study

  NCT05975658· Children's Mercy Hospital Kansas City· Source

• Completed

  Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)

  NCT05312177· Carelon Research· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Completed

  A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

  NCT04992312· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

  NCT05326516· Phase 1· Syndax Pharmaceuticals· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

  NCT05153317· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Afrezza® INHALE-1 Study in Pediatrics

  NCT04974528· Phase 3· Mannkind Corporation· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

  NCT06177691· Jaeb Center for Health Research· Source

• Completed

  A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

  NCT04699604· Phase 3· Bridgette Jones· Source

• Completed

  A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

  NCT04279613· Phase 1· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment

  NCT04400071· Indiana University· Source

• Completed

  Stay In Treatment for Pediatric Weight Management

  NCT04364282· Wake Forest University Health Sciences· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Completed

  Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

  NCT04183790· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Medication Adherence With Telehealthcare Medication Therapy Management

  NCT03978936· Johns Hopkins University· Source

• Terminated

  Open-Label Extension of Voxelotor

  NCT04188509· Phase 3· Pfizer· Source

• Completed

  Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children

  NCT03914547· Nemours Children's Clinic· Source

• Completed

  Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

  NCT03904134· Center for International Blood and Marrow Transplant Research· Source

• Completed

  CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

  NCT03924219· Vanderbilt University Medical Center· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)

  NCT03771508· Medtronic - MITG· Source

• Completed

  ATHN 7: Hemophilia Natural History Study

  NCT03619863· American Thrombosis and Hemostasis Network· Source

• Completed

  Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

  NCT03507491· Phase 1· Emory University· Source

• Completed

  Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia

  NCT03268421· Children's Hospital Medical Center, Cincinnati· Source

• Completed

  RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

  NCT03118986· Phase 2· The Hospital for Sick Children· Source

• Completed

  High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

  NCT02860039· Phase 2· Vanderbilt-Ingram Cancer Center· Source

• Recruiting

  Type 1 Diabetes Extension Study

  NCT02734277· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Pediatric Obesity Weight Evaluation Registry (POWER) Study

  NCT02121132· Children's Hospital Medical Center, Cincinnati· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

  NCT01467427· Phase 3· Novo Nordisk A/S· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Congenital heart disease24 works · 6 trials
• Acute lymphoblastic leukaemia17 works · 7 trials
• Down syndrome12 works · 2 trials
• Childhood cancers10 works · 20 trials